BlackRock Institutional Trust’s TherapeuticsMD TXMD Stock Holding History

BlackRock Institutional Trust’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$24.9M	Buy	86,143 +6,023	+8%	+$1.87M	﹤0.01%	1815
2016 Q3	$27.3M	Buy	80,120 +6,161	+8%	+$2.25M	﹤0.01%	1664
2016 Q2	$31.4M	Buy	73,959 +692	+0.9%	+$285K	0.01%	1542
2016 Q1	$23.4M	Buy	73,267 +6,768	+10%	+$2.31M	﹤0.01%	1711
2015 Q4	$34.5M	Buy	66,499 +2,356	+4%	+$870K	0.01%	1487
2015 Q3	$18.8M	Buy	64,143 +15,710	+32%	+$5.58M	﹤0.01%	1885
2015 Q2	$19M	Buy	48,433 +6,477	+15%	+$2.29M	﹤0.01%	1957
2015 Q1	$12.7M	Buy	41,956 +12,501	+42%	+$3.05M	﹤0.01%	2237
2014 Q4	$6.55M	Buy	29,455 +6,646	+29%	+$1.37M	﹤0.01%	2607
2014 Q3	$5.29M	Buy	22,809 +506	+2%	+$127K	﹤0.01%	2665
2014 Q2	$4.93M	Buy	22,303 +2,915	+15%	+$649K	﹤0.01%	2795
2014 Q1	$6.12M	Buy	19,388 +996	+5%	+$317K	﹤0.01%	2702
2013 Q4	$4.79M	Buy	18,392 +216	+1%	+$47.3K	﹤0.01%	2806
2013 Q3	$2.66M	Buy	18,176 +1,572	+9%	+$190K	﹤0.01%	2996
2013 Q2	$2.52M	Buy	+16,604	New	+$2.27M	﹤0.01%	2984

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BlackRock Institutional Trust's TXMD Position: Q4 2016 in Review

BlackRock Institutional Trust increased its TherapeuticsMD (TXMD) stake by 7.5% in Q4 2016, buying an estimated $1.87M and bringing the position to 86,143 shares worth $24.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1815.

BlackRock Institutional Trust first reported a position in TXMD in Q2 2013 and has held it in 15 quarters since. The position peaked at $34.5M in Q4 2015. 146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

BlackRock Institutional Trust held 86,143 shares of TherapeuticsMD worth $24.9M as of Q4 2016.
BlackRock Institutional Trust bought 6,023 TherapeuticsMD shares in Q4 2016, an estimated $1.87M.
TherapeuticsMD made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1815 holding.
BlackRock Institutional Trust first reported a position in TherapeuticsMD in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's TherapeuticsMD position peaked at $34.5M in Q4 2015.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.